2023 International Congress » Parkinson's Disease: Pathophysiology

A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

D. Chouhan, K. Browne, R. Patel, S. Karandikar, F. Laimo, D. Cullen, J. Duda (Philadelphia, USA)

Aging brain in Parkinson`s: A study through biomarkers

V. Rama Raju (Hyderabad, India)

Alzheimer’s Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study

D. Coughlin, K. Hwang, E. Bayram, D. Galasko (San Diego, USA)

Amplifying or suppressing subthalamic beta oscillations in real-time in Parkinson’s disease using evoked interference deep brain stimulation (eiDBS): feasibility in the human

D. Escobar, B. Campbell, S. Mesbah, L. Favi Bocca, J. Liao, R. Rammo, S. Nagel, A. Machado, K. Baker (Cleveland, USA)

Analysis of subthalamic-nuclei deep brain stimulation using radiomic feature-manifestations: a quantitative approach

V. Rama Raju (Hyderabad, India)

Assessing akinesia domains during multitasking in Parkinson’s disease

V. Dzialas, M. Banwinkler, M. Höhnig, T. van Eimeren (Cologne, Germany)

Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia

A. Siderowf, L. Concha-Marambio, D. Lafontant, R. Alcalay, L. Chahine, T. Faroud, D. Galasko, K. Kieburt, K. Merchant, B. Mollenhauer, K. Poston, J. Seibyl, C. Tanner, T. Simuni, D. Weintraub, A. Videnovic, S. Choi, C. Caspell-Garcia, C. Coffey, M. Frasier, L. Oliveira, S. Hutten, T. Sherer, C. Soto, K. Marek (Philadelphia, USA)

Association between severity of freezing of gait and turning characteristics in Parkinson’s disease

SM. Cheon, JW. Kim (BUSAN, Republic of Korea)

Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders

KA. Woo, HJ. Chang, JY. Joo, JH. Shin, SY. Kim, SM. Lee, BR. Jin, HY. Jeon, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease

A. Brück, R. Ajalin, H. Al-Abdulrasul, H. Zetterberg, K. Blennow, E. Löyttyniemi, J. Rinne (Turku, Finland)

Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming

T. Nakamura, H. Nishijima, F. Mori, I. Kinoshita, T. Kon, C. Suzuki, K. Wakabayashi, M. Tomiyama (Hirosaki, Japan)

Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis

SM. Li, YC. Zheng, C. Yang, JY. Wu, ZW. Yu, Y. Jiang, T. Feng (Beijing, China)

Concordant RNA patterns in Parkinson’s disease brain and peripheral blood.

K. Irmady, C. Hale, J. Fak, R. Qadri, T. Carroll, S. Przedborski, R. Darnell, S. Simelane (NEW YORK, USA)

Correlation between levels of plasma neurofilament light chain and freezing of gait in Parkinson’s disease

Y. Zhu, X. Yang, H. Ren, A. Pang (Kunming, China)

Decreased α-synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson’s disease

V. Gao, J. Briano, L. Komer, C. Crawford, C. Henchcliffe, A. Lee, J. Burré (Brooklyn, USA)

Diagnostic Utility of Blood α-Synuclein in Parkinson’s Disease: A Systematic Review and Meta-analysis

D. Su, L. Luo, J. Lam, T. Feng (Beijing, China)

Distinct characteristics of gut microbiome in patients with Parkinson’s disease according to the presence of premotor REM sleep behavior disorders

S. Jo, JY. Lee, JW. Bae, SJ. Chung (Seoul, Republic of Korea)

Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP

S. Choudhury, P L. Abhilash, P. Alladi (Bengaluru, India)

Dysphagia and dopaminergic neurodegeneration in Parkinson’s Disease

S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

Effect of multi-strain probiotics on gut microbiome and metabolites in Parkinson’s Disease

JW. Hor, SY. Lim, CW. Chong, SL. Song, CSJ. Teh, TS. Toh, JL. Lim, KY. Khaw, AH. Tan (Kuala Lumpur, Malaysia)

Effect of ventricular morphometrics on the treatment of Parkinson’s disease

JJ. Lee, YB. Yong, JS. Baik (Goyang-si, Republic of Korea)

Elevated plasma CREG1 levels are linked to a lower risk of Parkinson’s disease

X. Guo, R. Zhou, G. Tian, R. Li (Xi'an, China)

Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles

C. Agua Villa, H. Siebner, M. Rickhag (Hvidovre, Denmark)

Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease

JW. Hor, SY. Lim, TS. Toh, CW. Chong, CSJ. Teh, SL. Song, KY. Khaw, AH. Tan (Kuala Lumpur, Malaysia)

Flavonoid intake and risk of Parkinson’s Disease

H. Sandoval Insausti, K. Bjornevik, J. Chavarro, M. Cortese, M. Flores, A. Hung, M. Schwarzschild, T. Yeh, A. Ascherio (Boston, USA)

Heart-rate variability as a new marker for freezing predisposition in Parkinson’s disease

B. Heimler, O. Koren, R. Inzelberg, U. Rosenblum, S. Hassin-Baer, G. Zeilig, R. Bartsch, M. Plotnik (Tel Hashomer, Israel)

Identification of potential oxidative biomarkers in saliva of Parkinson’s disease patients

J. Rungta, A. Roy, S. Choudhury, S. Ansari, P. Chatterjee, R. Khatun, R. Pramanik, S. Dey, H. Kumar (Kolkata, India)

Incidence and Predictors of Axial Postural Abnormalities in Parkinson disease: data from the PPMI cohort

CA. Artusi, C. Campisi, C. Ledda, K. Tsukita, D. Rinaldi, L. Lopiano, M. Fabbri (Torino, Italy)

Incidence of Parkinson’s disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort

SJ. Chung, SH. Kang, S-J. Moon, M. Kang, GJ. Cho, S-B. Koh (Goyang, Republic of Korea)

IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy

A. Okuzumi, T. Hatano, G. Matsumoto, N. Hattori (Tokyo, Japan)

Modeling Parkinson’s disease progression accounting for the effect of symptomatic treatments in the Parkinson’s Progression Markers Initiative study

B. Ribba, T. Simuni, K. Marek, A. Siderowf, L. Chahine, C. Diack, A. Monnet, B. Ricci, T. Nikolcheva, G. Pagano (Basel, Switzerland)

Morphometric assessment of age-associated neuronal changes in the human locus coeruleus

A. Bhattacharya, A. Mahadevan, R. Manjithaya, T. Yasha, P. Alladi (Bengaluru, India)

Olfactory dysfunction as a predictor of the future development of parkinsonism in COVID patients

M. de Rosa, D. Calisi, L. Bonanni, M. Onofrj (Chieti, Italy)

Orthostatic vital sign changes do not influence 5-year motor outcomes in PD

J. Li, J. Ruiz Tejeda, D. Tran, S. Nguyen, N. Phielipp (Irvine, USA)

Pareidolias and color discrimination deficits differently correlate with cognitive dysfunction in prodromal Lewy body disease

S. Kim, JH. Choi, KA. Woo, JY. Joo, HJ. Chang, B. Jeon, JY. Lee (Seoul, Republic of Korea)

Parkinson’s disease and human gut microbiota in an Egyptian population: a pilot study

S. Hashish, M. Hirose, A. Moustafa, A. Shalash, S. Ibrahim, M. Salama (Cairo, Egypt)

Pathological findings in a case of DJ-1 early onset Parkinson’s disease

M. Schoenberg, D. Narendra, L. Kenyon, TW. Liang (Philadelphia, USA)

Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity

B. Huxford, C. Simonet-Hernandez, L. Pérez-Carbonell, A. Schrag, R. Dobson, A. Noyce (London, United Kingdom)

Prognostic significance of peripheral neutrophils and lymphocytes in early Parkinson’s disease

JS. Jun, R. Kim (Seoul, Republic of Korea)

Reproductive life factors and sex hormones in post-menopausal female patients with Parkinson’s Disease

R. Bovenzi, M. Conti, G. Sancesario, R. Cerroni, M. Pierantozzi, A. Stefani, N. Mercuri, T. Schirinzi (Rome, Italy)

Risk of Parkinson’s Disease due to Helicobacter Pylori and High Salt Consumption

V. Balendra (Park Ridge, USA)

Salivary α-synuclein in Parkinson’s disease – a pilot study

M. Kaiserova, D. Hrabos, M. Levkova, M. Kavalkova, R. Kopacik, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

Self-perception of symptoms lateralization and association with symptoms severity in Parkinson’s disease.

V. Silva Costa, T. Figo Rocha, M. Oliveira Menacho, T. Silva Brito, A. Lepesteur Gianlorenço (São Carlos, Brazil)

Serum Metabolomics in Parkinson’s Disease: Correlations with Fecal Microbiome, Fecal Metabolomics and Clinical Status

TS. Toh, CW. Chong, MF. Loke, JW. Hor, LC. Lit, J. Bowman, SL. Song, CSJ. Teh, S-Y. Lim, AH. Tan (Kuala Lumpur, Malaysia)

Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease

S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson’s disease

S. Murayama, Y. Saito (Osaka, Japan)

The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease

E. Gök Dursun, M. Karataş, M. çetinkaya, K. Karlı Oğuz, B. Tel, G. Yalçın çakmaklı, B. Elibol (Ankara, Turkey)

Use of insect model to study Parkinson’s disease pathophysiology by inducing GSH-depletion and behavioral deficits among larvae: Evidences of ameliorative properties of phytoconstituents

G. Chandran, R. D'Silva, M. Muralidhara (MYSURU, India)